24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients

NCT03702829 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
31
Enrollment
OTHER
Sponsor class

Stopped recruitment of new patients not possible during Covid 19 epidemic

Conditions

Interventions

Sponsor

Brigham and Women's Hospital